Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02468583 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee
A Phase 2 study, sponsored by Pacira Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02468583 is a Phase 2 study that was terminated before completion, run by Pacira Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT02468583, a Phase 2 study, was terminated before completion, sponsored by Pacira Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study was a double-blind, randomized, parallel group, proof of concept study comparing FX006 to Kenalog®-40 (triamcinolone acetonide injectable suspension, USP) in patients with post-traumatic osteoarthritis of the knee.
Interventions
- DRUG FX006 32 mg
- DRUG TCA IR 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02468583
The ClinicalTrials.gov registry entry for NCT02468583 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FX006 32 mg is the first listed.
NCT02468583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02468583 about?
NCT02468583 is a clinical study titled "Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee". This study was a double-blind, randomized, parallel group, proof of concept study comparing FX006 to Kenalog®-40 (triamcinolone acetonide injectable suspension, USP) in patients with post-traumatic osteoarthritis of the knee.
What is the current status of trial NCT02468583?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-02. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02468583?
The interventions under investigation include: FX006 32 mg (DRUG), TCA IR 40 mg (DRUG).
Who is sponsoring clinical trial NCT02468583?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.